Abbott -with- Aventis (Pharmaceuticals) [2004] IECompA M04028 (05 May 2004)

Abbott -with- Aventis (Pharmaceuticals) [2004] IECompA M04028 (05 May 2004)

The Competition Authority found no evidence that the proposed transaction would substantially lessen competition in the relevant markets.

Citation
[2004] IECompA M04028
Parties
Acquirer: Abbott Laboratories and affiliates; Target: Aventis S.A.
Jurisdiction
Ireland
Judgment Date
05 May 2004
Procedural Posture
Merger Notification / Preliminary Investigation (phase 1)
Outcome
approved
Legal Topics
Merger Control, Pharmaceutical Sector
Competition Law Merger Control Pharmaceutical Sector

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 1 Authorities cited 1 Party arguments 2
Sign in to unlock

Parties

Abbott Laboratories and affiliates

Acquirer

Aventis S.A.

Target

Procedural Posture

Merger Notification / Preliminary Investigation (phase 1)

Legal Issues

  1. 1 Whether the proposed acquisition of Aventis's Trandolapril and Trandolapril/Verapamil business by Abbott raises competition concerns

Ratio Decidendi

The Competition Authority found no evidence that the proposed transaction would substantially lessen competition in the relevant markets.

Court Disposition

approved

Orders

  • The proposed transaction is cleared and may proceed.